Werewolf Therapeutics Inc... (HOWL)
Werewolf Therapeutics Inc. (HOWL) Stock Price, Analysis & Data
| Bid | 0.28 |
| Market Cap | 18.21M |
| Revenue (ttm) | 21M |
| Net Income (ttm) | -34.61M |
| Beta | 0.29 |
| EPS (ttm) | -0.73 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.38 |
| P/B (ttm) | 1.12 |
| P/S (ttm) | 0.87 |
| Earnings Date | Oct 30, 2026 |
| Ask | 0.48 |
| Volume | 175,838 |
| Avg. Volume (20D) | 749,372 |
| Open | 0.40 |
| Previous Close | 0.38 |
| Day's Range | 0.36 - 0.40 |
| 52-Week Range | 0.27 - 2.38 |
| Analyst | n/a |
| Price Target | 7 (1791.89%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About HOWL
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead prod...
Financial Performance
In 2025, Werewolf Therapeutics's revenue was 0, a decrease of -100% compared to the previous year's 1.89M. Earnings were -60.82M, a decrease of -13.75%.
Financial StatementsAnalyst Forecast
According to 1 analyst ratings, the average rating for HOWL stock is "null". The 12-month stock price forecast is 7, which is upside of 1791.89% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
